Assessing metastasis risk after pre-operative anti-angiogenic therapy
نویسندگان
چکیده
Anti-angiogenic drugs are approved for the treatment of several cancer types, generally in the inoperable locally advanced or metastatic setting and in combination with other anti‐cancer agents. Recent clinical studies also suggest that anti‐angiogenic drugs can be useful in the pre‐operative (neoadjuvant) setting, by facilitating the shrinkage of the primary tumour and its surgical resection. However, the effects of neoadjuvant anti‐angiogenic therapy on the ability of tumours to form distant metastases are unclear. In this issue of EMBO Molecular Medicine, Ebos et al (2014) present carefully performed pre-clinical studies in mice that analyse the effects of pre-operative anti-angiogenic therapy on tumour metastasis and survival.
منابع مشابه
A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update
At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of developing metastasis and subsequent disease-related death. Given this, it is important that novel therapies are investigated in the adjuvant mel...
متن کاملRole of Pre-Operative Serum CA 15-3 Level in risk stratification of Breast Cancer
Background: Cancer Antigen 15-3, a derivative of a large transmembrane glycoprotein polymorphic epithelial mucin derived from MUC1 gene is a reliable marker in identifying patients who would benefit most from adjuvant therapy. Materials & Methods: Aimed at assessing the overall risk, possibility of distant metastasis and need for adjuvant therapy we assessed the role of pre-operative CA 15-3 an...
متن کاملMetabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality
Anti-angiogenic therapy has increased the progression-free survival of many cancer patients but has had little effect on overall survival, even in colon cancer (average 6-8 weeks) due to resistance. The current licensed targeted therapies all inhibit VEGF signalling (Table 1). Many mechanisms of resistance to anti-VEGF therapy have been identified that enable cancers to bypass the angiogenic bl...
متن کاملPrevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin.
BACKGROUND We have previously offered data suggesting a positive linkage of postoperative up-regulation of systemic angiogenic activity and postoperative progression of pulmonary metastasis in osteosarcoma. The finding that the significant down-regulation of endostatin was critical in angiogenic elevation after primary tumor removal suggests that endostatin is a candidate for antiangiogenic the...
متن کاملRelation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients.
BACKGROUND & OBJECTIVE The primary mediator of angiogenesis is vascular endothelial growth factor (VEGF). It is well documented that angiogenic activity in human cancer depends on nitric oxide (NO) levels in tissues. Additionally, urokinase type plasminogen activator (u-PA) plays a role in cell adhesion and migration. Serum VEGF and its relationship between NO and u-PA concentrations are poorly...
متن کامل